International Journal of Radiation Oncology * Biology * Physics
Volume 76, Issue 3 , Pages 666-678 , 1 March 2010

Current Management of Primary Central Nervous System Lymphoma

  • Christopher J. Schultz, M.D.
    • ,
  • Joseph Bovi, M.D.

      Affiliations

    • Corresponding Author InformationReprint requests to: Joseph Bovi, M.D., Department of Radiation Oncology, Medical College of Wisconsin, 9200 W. Wisconsin Avenue, Milwaukee, WI 53226. Tel: (414) 805-4472; Fax (414) 805-4369

Received 11 March 2009 ,Revised 22 September 2009 ,Accepted 21 October 2009.

References 

  1. U.S. cancer statistics working group. united states cancer statistics: 1999–2004 incidence and mortality web-based report. atlanta: U.S. department of health and human services, centers for disease control and prevention and national cancer institute [homepage on the Internet].. 2007 [cited 1/22/2008]. Available from: http://apps.nccd.cdc.gov/uscs/Table.aspx?Group=TableAll&Year=2004&Display=n. Last accessed December 12, 2009.
  2. CBTRUS . statistical report:Primary brain tumors in the united states, 1998-2002. Hinsdale, IL: Published by the Central Brain Tumor Registry of the United States; 2005;
  3. Schabet M. Epidemiology of primary CNS lymphoma. J Neurooncol. 1999 Jul;43(3):199–201
  4. Bataille B, Delwail V, Menet E, Vandermarco P, Ingrand I, Wager M, et al. Primary intracerebral malignant lymphoma: Report of 248 cases. J Neurosurg. 2000;92:261–266
  5. Partap S, Spence AM. Spontaneously relapsing and remitting primary CNS lymphoma in an immunocompetent 45-year-old man. J Neurooncol. 2006 Dec;80(3):305–307
  6. Shenkier TN. Unusual variants of primary central nervous system lymphoma. Hematology - Oncology Clinics of North America. 2005;vi; Aug;19(4):651–64
  7. Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. Journal of Clinical Oncology. 2005 Aug 1;23(22):5034–5043
  8. Correa D, Maron L, Harder H, Klein M, Armstrong C, Calabrese P, et al. Cognitive functions in primary central nervous system lymphoma: Literature review and assessment guidelines. Ann Oncol. 2007 July 1;18(7):1145–1151
  9. Ekstein D, Ben-Yehuda D, Slyusarevsky E, Lossos A, Linetsky E, Siegal T. CSF analysis of IgH gene rearrangement in CNS lymphoma: Relationship to the disease course. J Neurol Sci. 2006 Aug 15;247(1):39–46
  10. Cinque P, Brytting M, Vago L, Castagna A, Parravicini C, Zanchetta N, et al. Epstein-barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system. Lancet. 1993 Aug 14;342(8868):398–401
  11. Yu H, Xie Y, Wang G. [The clinical features and prognostic factors of 22 patients with primary central nervous system lymphoma]. Chung-Hua Nei Ko Tsa Chih Chinese Journal of Internal Medicine. 2001 May;40(5):325–328
  12. De Luca A, Antinori A, Cingolani A, Larocca LM, Linzalone A, Ammassari A, et al. Evaluation of cerebrospinal fluid EBV-DNA and IL-10 as markers for in vivo diagnosis of AIDS-related primary central nervous system lymphoma. Br J Haematol. 1995 Aug;90(4):844–849
  13. Coulon A, Lafitte F, Hoang-Xuan K, Martin-Duverneuil N, Mokhtari K, Blustajn J, et al. Radiographic findings in 37 cases of primary CNS lymphoma in immunocompetent patients. Eur Radiol. 2002 Feb;12(2):329–340
  14. Thurnher MM, Rieger A, Kleibl-Popov C, Settinek U, Henk C, Haberler C, et al. Primary central nervous system lymphoma in AIDS: A wider spectrum of CT and MRI findings. Neuroradiology. 2001 Jan;43(1):29–35
  15. Kuker W, Nagele T, Korfel A, Heckl S, Thiel E, Bamberg M, et al. Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol. 2005 Apr;72(2):169–177
  16. Raizer JJ, Koutcher JA, Abrey LE, Panageas KS, DeAngelis LM, Lis E, et al. Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma. J Neurooncol. 2005 Jan;71(2):173–180
  17. Villringer K, Jager H, Dichgans M, Ziegler S, Poppinger J, Herz M, et al. Differential diagnosis of CNS lesions in AIDS patients by FDG-PET. J Comput Assist Tomogr. 1995 Jul-Aug;19(4):532–536
  18. Mohile NA, DeAngelis LM, Abrey LE. The utility of body FDG PET in staging primary central nervous system lymphoma. Neuro-oncol. 2008 April 1;10(2):223–228
  19. Palmedo H, Urbach H, Bender H, Schlegel U, Schmidt-Wolf IG, Matthies A, et al. FDG-PET in immunocompetent patients with primary central nervous system lymphoma: Correlation with MRI and clinical follow-up. European Journal of Nuclear Medicine & Molecular Imaging. 2006 Feb;33(2):164–168
  20. Paulus W. Classification, pathogenesis. and molecular pathology of primary CNS lymphomas. J Neurooncol. 1999;[cited 1/2/2008];43(3):203–8
  21. DeAngelis LM, Wong E, Rosenblum M, Furneaux H. Epstein-barr virus in acquired immune deficiency syndrome (AIDS) and non-AIDS primary central nervous system lymphoma. Cancer. 1992 Sep 15;70(6):1607–1611
  22. Rao CR, Jain K, Bhatia K, Laksmaiah KC, Shankar SK. Association of primary central nervous system lymphomas with the epstein-barr virus. Neurol India. 2003 Jun;51(2):237–240
  23. Nelson DF, Martz KL, Bonner H, Neson JS, Newall J, Kerman HD, et al. Non-hodgkin's lymphoma of the brain: Can high dose, large volume radiation therapy improve survival? report on a prospective trial by the radiation therapy oncology group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys. 1992;23:9–17
  24. O'Neill BP, O'Fallon JR, Earle JD, Colgan JP, Brown LD, Krigel RL. Primary central nervous system non-hodgkin's lymphoma: Survival advantages with combined initial therapy?. Int J Radiat Oncol Biol Phys. 1995 10/15;33(3):663–673
  25. Schultz CJ, Scott C, Sherman W, Donahue B, Fields J, Murray K, et al. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: Initial report of radiation therapy -oncology group protocol 88-06. J Clin Oncol. 1996;14:556–564
  26. DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ. Radiation Therapy Oncology Group Study,93-10. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation therapy oncology group study 93-10. Journal of Clinical Oncology. 2002 Dec 15;20(24):4643–4648
  27. Corry J, Smith JG, Wirth A, Quong G, Liew KH. Primary central nervous system lymphoma: Age and performance status are more important than treatment modality. Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):615–620
  28. Bessell EM, Graus F, Lopez-Guillermo A, Lewis SA, Villa S, Verger E, et al. Primary non-hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: Long-term survival and prognostic factors. Int J Radiat Oncol Biol Phys. 2004 6/1;59(2):501–508
  29. Ferreri AJM, Blay J, Reni M, Pasini F, Spina M, Ambrosetti A, et al. Prognostic scoring system for primary CNS lymphomas: The international extranodal lymphoma study group experience. J Clin Oncol. 2003 January 15;21(2):266–272
  30. Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, et al. Primary central nervous system lymphoma: The memorial sloan-kettering cancer center prognostic model. Journal of Clinical Oncology. 2006 Dec 20;24(36):5711–5715
  31. Larocca LM, Capello D, Rinelli A, Nori S, Antinori A, Gloghini A, et al. The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-related B cells. Blood. 1998 Aug 1;92(3):1011–1019
  32. Braaten KM, Betensky RA, de Leval L, Okada Y, Hochberg FH, Louis DN, et al. BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res. 2003 March 1;9(3):1063–1069
  33. Murray K, Kun L, Cox J. Primary malignant lymphoma of the central nervous system: Results of the treatment of 11 cases and review of the literature. J Neurosurg. 1986;65:600–607
  34. Corn BW, Dolinskas C, Scott C, Donahue B, Schultz C, Nelson DF, et al. Strong correlation between imaging response and survival among patients with primary central nervous system lymphoma: A secondary analysis of RTOG studies 83-15 and 88-06. Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):299–303
  35. DeAngelis LM, Yahalom J, Thaler HT, Kher U. Combined modality therapy for primary CNS lymphoma. Journal of Clinical Oncology. 1992 Apr;10(4):635–643
  36. Fisher B, Seiferheld W, Schultz C, DeAngelis L, Nelson D, Schold SC, et al. Secondary analysis of radiation therapy oncology group study (RTOG) 9310: An intergroup phase II combined modality treatment of primary central nervous system lymphoma. J Neurooncol. 2005 Sep;74(2):201–205
  37. Bessell EM, Lopez-Guillermo A, Villa S, Verger E, Nomdedeu B, Petit J, et al. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: An analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. Journal of Clinical Oncology. 2002 Jan 1;20(1):231–236
  38. Shah GD, Yahalom J, Correa DD, Lai RK, Raizer JJ, Schiff D, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. Journal of Clinical Oncology. 2007 Oct 20;25(30):4730–4735
  39. Ott RJ, Brada M, Flowers MA. Measurements of blood-brain barrier permiability in patients undergoing radiotherapy and chemotherapy for primary cerebral lymphoma. Eur J Cancer. 1991;27:1356–1361
  40. Khan RB, Shi W, Thaler HT, DeAngelis LM, Abrey LE. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?. J Neurooncol. 2002 Jun;58(2):175–178
  41. Neuwelt E, Goldman D, Dahlborg S, Crossen J, Ramsey F, Roman-Goldstein S, et al. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: Prolonged survival and preservation of cognitive function. J Clin Oncol. 1991 September 1;9(9):1580–1590
  42. Montemurro M, Kiefer T, Schuler F, Al-Ali HK, Wolf HH, Herbst R, et al. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: Results of the multicenter ostdeutsche studiengruppe hamato-onkologie OSHO-53 phase II study. Annals of Oncology. 2007 Apr;18(4):665–671
  43. Colombat P, Lemevel A, Bertrand P, Delwail V, Rachieru P, Brion A, et al. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: A multicenter phase II study of the GOELAMS group. Bone Marrow Transplant. 2006 Sep;38(6):417–420
  44. Soussain C, Suzan F, Hoang-Xuan K, Cassoux N, Levy V, Azar N, et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. Journal of Clinical Oncology. 2001 Feb 1;19(3):742–749
  45. Enting RH, Demopoulos A, DeAngelis LM, Abrey LE. Salvage therapy for primary CNS lymphoma with a combination temozolamide and rituximab. Neurology. 2004;40:1682–1688
  46. Plotkin SR, Betensky RA, Hochberg F. Treatment of relapsed central nervous system lymphoma with high dose methotrexate. Clin Cancer Res. 2004;10:5643–5646
  47. Herrlinger U, Brugger W, Bamberg M, Kuker W, Dichgans J, Weller M. PCV salvage chemotherapy for for recurrent primary CNS lymphoma. Neurology. 2000;54:1707–1708
  48. Nguyen P, Chakravarti A, Finkelstein D, Hochberg F, Batchelor TT, Loeffler J. Results of whole brain radiation as salvage of methotrexate failurefor immunocompetent patients with primary CNS lymphoma. J Clin Oncol. 2005;23:1507–1513
  49. Voloschin AD, Betensky RA, Wen PY, Hochberg F, Batchelor T. Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J Neurooncol. 2008;86:211–215
  50. Kasamon YL, Ambinder RF. AIDS-related primary central nervous system lymphoma. Hematology - Oncology Clinics of North America. 2005;vi-vii; Aug;19(4):665–87
  51. Ambinder RF, Lee S, Curran WJ, Sparano JA, Krigel RL, McArthur J, et al. Phase II intergroup trial of sequential chemotherapy and radiationtherapy for AIDS-related primary central nervous system lymphoma. Cancer Therapy. 2003;1:215–221
  52. Hoffmann C, Tabrizian S, Wolf E, Eggers C, Stoehr A, Plettenberg A, et al. Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. AIDS. 2001 Nov 9;15(16):2119–2127
  53. Pajonk F, McBride WH. Survival of AIDS patients with primary central nervous system lymphoma may be improved by the radiosensitizing effects of highly active antiretroviral therapy. AIDS. 2002 May 24;16(8):1195–1196
  54. Newell ME, Hoy JF, Cooper SG, DeGraaff B, Grulich AE, Bryant M, et al. Human immunodeficiency virus-related primary central nervous system lymphoma: Factors influencing survival in 111 patients. Cancer. 2004 Jun 15;100(12):2627–2636
  55. Raez L, Cabral L, Cai J, Landy H, Sfakianakis G, Byrne GE, et al. Treatment of AIDS-related primary central nervous system lymphoma with zidovudine, ganciclovir, and interleukin 2. AIDS Res Hum Retroviruses. 1999 05/20;15(8):713–719
  56. Aboulafia DM. Interleukin-2, ganciclovir, and high-dose zidovudine for the treatment of AIDS-associated primary central nervous system lymphoma. Clinical Infectious Diseases. 2002 Jun 15;34(12):1660–1662
  57. Bossolasco S, Falk KI, Ponzoni M, Ceserani N, Crippa F, Lazzarin A, et al. Ganciclovir is associated with low or undetectable epstein-barr virus DNA load in cerebrospinal fluid of patients with HIV-related primary central nervous system lymphoma. Clinical Infectious Diseases. 2006 Feb 15;42(4):e21–e25
  58. Abrey LE, Correa DD. Treatment-related neurotoxicity. Hematology - Oncology Clinics of North America. 2005;viii; Aug;19(4):729–38
  59. Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. Journal of Clinical Oncology. 2006 Oct 1;24(28):4570–4574
  60. Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: The next step. Journal of Clinical Oncology. 2000 Sep;18(17):3144–3150
  61. Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. Journal of Clinical Oncology. 1998 Mar;16(3):859–863
  62. Ferreri AJ, Abrey LE, Blay JY, Borisch B, Hochman J, Neuwelt EA, et al. Summary statement on primary central nervous system lymphomas from the eighth international conference on malignant lymphoma, lugano, switzerland, june 12 to 15, 2002. Journal of Clinical Oncology. 2003 Jun 15;21(12):2407–2414
  63. Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, Van't Veer M, Hansen M, Soubeyran P, et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European organization for research and treatment of cancer lymphoma group phase II trial 20962. Journal of Clinical Oncology. 2003 Dec 15;21(24):4483–4488
  64. O'Brien PC, Roos DE, Pratt G, Liew KH, Barton MB, Poulsen MG, et al. Combined-modality therapy for primary central nervous system lymphoma: Long-term data from a phase II multicenter study (trans-tasman radiation oncology group). Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):408–413
  65. Blay J, Bouhour D, Carrie C, Bouffet E, Brunat-Mentigny M, Philip T, et al. The C5R protocol: A regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-hodgkin's lymphoma of patients with no known cause of immunosuppression [see comments]. Blood. 1995 October 15;86(8):2922–2929
  66. Brada M, Hjiyiannakis D, Hines F, Traish D, Ashley S. Short intensive primary chemotherapy and radiotherapy in sporadic primary CNS lymphoma (PCL). Int J Radiat Oncol Biol Phys. 3/15. 1998;40(5):1157–1162
  67. Pels H, Schmidt-Wolf IG, Glasmacher A, Schulz H, Engert A, Diehl V, et al. Primary central nervous system lymphoma: Results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. Journal of Clinical Oncology. 2003 Dec 15;21(24):4489–4495
  68. Gerstner ER, Carson KA, Grossman SA, Batchelor TT. Long term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiation. Neurology. 2008 January 29;70(5):401–402
  69. Batchelor T, Carson K, O'Neill A, Grossman SA, Alavi J, New P, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: A report of NABTT 96-07. J Clin Oncol. 2003;21:1044–1049
  70. Hoang-Xuan K, Taillandier L, Chinot O, Soubeyran P, Bogdhan U, Hildebrand J, et al. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: A multicenter phase II study (26952) of the european organization for research and treatment of cancer brain tumor group. Journal of Clinical Oncology. 2003 Jul 15;21(14):2726–2731
  71. Sandor V, Stark-Vancs V, Pearson D, Nussenblat R, Whitcup SM, Brouwers P, et al. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. Journal of Clinical Oncology. 1998 Sep;16(9):3000–3006
  72. Dahlborg SA, Henner WD, Crossen JR, Tableman CM, Petrillo A, Braziel R, et al. Non-AIDS primary CNS lymphoma: First example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy. Cancer J Sci Am. 1996 May-Jun;[cited 10/29/2008];2(3):166–174

 Conflict of interest: none.

PII: S0360-3016(09)03389-6

doi: 10.1016/j.ijrobp.2009.10.011

International Journal of Radiation Oncology * Biology * Physics
Volume 76, Issue 3 , Pages 666-678 , 1 March 2010

Article Tools

* Image Usage & Resolution